Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
UBS
Covington
US Army
Citi
Fuji
Dow
Accenture
Queensland Health
Chubb

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,919,775

« Back to Dashboard

Which drugs does patent 5,919,775 protect, and when does it expire?

Patent 5,919,775 protects ORACEA and is included in one NDA.

This patent has eleven patent family members in seven countries.
Summary for Patent: 5,919,775
Title: Method for inhibiting expression of inducible nitric oxide synthase with tetracycline
Abstract:The invention is a method of inhibiting the production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo biological system. The method employs a tetracycline compound to inhibit the production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the biological system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.
Inventor(s): Amin; Ashok R. (Union, NJ), Abramson; Steven B. (Rye, NY), Golub; Lorne M. (Smithtown, NY), Ramamurthy; Nungavaram S. (Smithtown, NY), McNamara; Thomas F. (Port Jefferson, NY), Greenwald; Robert A. (Melville, NY), Trachtman; Howard (New Rochelle, NY)
Assignee: The Research Foundation of The State University of New York (Stony Brook, NY) Hospital For Joint Diseases (New York, NY)
Application Number:09/061,286
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 5,919,775

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp ORACEA doxycycline CAPSULE;ORAL 050805-001 May 26, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,919,775

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,789,395 Method of using tetracycline compounds for inhibition of endogenous nitric oxide production ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,919,775

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 334512 ➤ Subscribe
South Korea 100554859 ➤ Subscribe
South Korea 20000035881 ➤ Subscribe
Japan 4451930 ➤ Subscribe
Japan 2002513386 ➤ Subscribe
European Patent Office 0966525 ➤ Subscribe
Canada 2670296 ➤ Subscribe
Canada 2264552 ➤ Subscribe
Australia 718234 ➤ Subscribe
Australia 4080897 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Fish and Richardson
Colorcon
Mallinckrodt
Express Scripts
Fuji
AstraZeneca
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot